Table 4 Characteristics of patients between <1.0 mg/kg group and 1.0-2.0 mg/kg group
Type | All Patients with AZA | <1.0 mg/kg group | 1.0-2.0 mg/kg group | P- value |
|---|---|---|---|---|
(n = 77) | (n = 39) | (n = 38) | ||
Gender | ||||
Male | 54 | 33 | 21 | 0.005 |
Female | 23 | 6 | 17 | |
Age at AZA treatment | 32.2 | 35.5 | 28.7 | 0.011 |
Duration from diagnosis to AZA treatment | 27.6 | 25.7 | 29.5 | 0.683 |
Age at diagnosis | ||||
A1 | 5 | 2 | 3 | 0.112 |
A2 | 59 | 27 | 32 | |
A3 | 13 | 10 | 3 | |
Location | ||||
L1 | 30 | 24 | 6 | <0.001 |
L2 | 10 | 5 | 5 | |
L3 | 35 | 9 | 26 | |
L4 | 15 | 9* | 6* | |
Behavior | ||||
B1 | 33 | 19 | 14 | 0.342 |
B2 | 40 | 19 | 21 | |
B3 | 7 | 2# | 5# | |
P | 24 | 11 | 13 | |
Surgery history | ||||
Yes | 28 | 15 | 13 | 0.698 |
No | 49 | 24 | 25 | |
Initial HBI | 5.0 | 4.8 | 5.1 | 0.624 |
Initial body weight (kg) | 52.9 | 60.5 | 45.2 | <0.001 |
Concomitant with 5-ASA/SASP | ||||
At initial | ||||
Yes | 50 | 29 | 21 | 0.079 |
No | 27 | 10 | 17 | |
At month 24 | ||||
Yes | 17 | 9 | 8 | 0.455 |
No | 22 | 9 | 13 | |
Adverse events | ||||
Yes | 21 | 13 | 8 | 0.226 |
No | 56 | 26 | 30 | |
Leucopenia | ||||
Yes | 8 | 4 | 4 | 1.000 |
No | 69 | 35 | 34 |